Aortic Stenosis and Cardiac Amyloidosis

Launched by MEDICAL UNIVERSITY OF VIENNA · Nov 8, 2023

Keywords

ClinConnect Summary

This clinical trial is focused on understanding a specific heart condition known as aortic stenosis (AS) when it occurs alongside cardiac amyloidosis (CA). Aortic stenosis is when the heart's valve thickens and narrows, making it harder for the heart to pump blood. Cardiac amyloidosis is a condition where abnormal proteins build up in the heart tissue, which can interfere with how the heart functions. The goal of this study is to gather information from about 300 patients with both conditions to better understand their health outcomes over time and to see how effective treatments that target amyloidosis are when combined with valve replacement surgery.

To participate in this study, patients must be between the ages of 65 and 74 and have significant aortic stenosis along with a confirmed diagnosis of cardiac amyloidosis. Unfortunately, those with less severe aortic stenosis or other types of cardiac amyloidosis will not be eligible. Participants will be monitored regularly, and their health will be assessed to track the progress of their conditions and the impact of treatments. This research is important as it aims to improve the understanding and management of these combined heart issues.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients with significant AS and a concomitant diagnosis of cardiac amyloidosis who are eligible for inclusion as per local permissions
• Exclusion Criteria:
• • Patients without significant AS (less than moderate AS)
• • Patients with other subtypes of cardiac amyloidosis (e.g., light chain)